Building access to the Regenstrief Institute is restricted through early 2021. More on our coronavirus precautions.
See our coronavirus precautions.

Regenstrief Institute research scientist Noll Campbell, PharmD, M.S., recently contributed to a study that made national headlines and provided more evidence that anticholinergic medications are linked to cognitive decline.

The results from the study, led by researchers at the University of California San Diego School of Medicine, were published in Neurology. The authors concluded that anticholinergics are associated with an increased risk of cognitive decline regardless of the presence of genetic or biomarker risk factors for Alzheimer’s disease.

Dr. Campbell consulted on the study, providing perspective on the data based on similar studies he has been involved with at Regenstrief and Indiana University School of Medicine.  He is listed as an author on the paper.

The past research conducted by Dr. Campbell and his colleagues also provides evidence establishing a link between the common type of medication and cognitive decline. He is now leading a clinical trial to determine if deprescribing anticholinergics improves cognition, which could in turn delay or prevent dementia.

In addition to his role as a research scientist at Regenstrief Institute, Dr. Campbell is an assistant professor of pharmacy practice at the Purdue University College of Pharmacy.

Related Influence

Nov 11, 2020 • Influence
Regenstrief leaders pioneer and lead in chief research information officer roles
As the amount of medical data and machine learning capabilities grow, the demand for chief research information officers (CRIO) has also increased. That role was pioneered by Regenstrief President and Chief Executive Officer Peter Embí, M.D., M.S. Regenstrief Chief Information Officer Umberto Tachinardi, M.D., MSc, was prominently featured in a Modern Healthcare and a GenomeWeb article discussing the importance of the position.   Dr. Embí was the first…
Continue Reading >
Oct 21, 2020 • Influence
COVID-19 and the ICU: Regenstrief expert shares experience providing care for patients
Indiana University Center for Aging Research at Regenstrief Institute Associate Director Babar Khan, M.D., M.S., has been treating patients in the intensive care unit (ICU) throughout the COVID-19 pandemic.   Dr. Khan said many patients continue to suffer from mental, physical and emotional impairments after being released from the ICU, and those problems can persist for months. He…
Continue Reading >